Co-Target(s) Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T69707 | Target Info | |||
Target Name | Proteasome (PS) | ||||
Target Type | Successful Target | ||||
Gene Name | NO-GeName | ||||
UniProt ID |
Co-Targets of This Target | Top | |||||
---|---|---|---|---|---|---|
Co-Target Name | Nuclear factor NF-kappa-B (NFKB) | Successful Target | ||||
UniProt ID | NFKB1_HUMAN; NFKB2_HUMAN; TF65_HUMAN; RELB_HUMAN; REL_HUMAN | |||||
Gene Name | NFKB1; NFKB2; RELA; RELB; REL | |||||
Synonyms |
Nuclear factor of kappa light polypeptide gene enhancer in B-cells; DNA-binding factor KBF
Click to Show/Hide
|
|||||
Representative Drug(s) | Bortezomib | Drug Info | IC50 = 9.7 nM | [1] | ||
Co-Target Name | Collagen (CO) | Successful Target | ||||
UniProt ID | CP3A4_HUMAN; CP3A5_HUMAN; CP3A7_HUMAN; CP343_HUMAN | |||||
Gene Name | NO-GeName | |||||
Representative Drug(s) | Carfilzomib | Drug Info | IC50 = 490 nM | [2] | ||
Co-Target Name | Cathepsin G (CTSG) | Clinical trial Target | ||||
UniProt ID | CATG_HUMAN | |||||
Gene Name | CTSG | |||||
Synonyms |
CG
Click to Show/Hide
|
|||||
Representative Drug(s) | Delanzomib | Drug Info | EC50 = 13.5 nM | Click to Show More | [3] | |
2 | Bortezomib | Drug Info | IC50 = 520 nM | [4] | ||
Co-Target Name | Glutathione S-transferase omega-1 (GSTO-1) | Literature-reported Target | ||||
UniProt ID | GSTO1_HUMAN | |||||
Gene Name | GSTO1 | |||||
Synonyms |
SPG-R; S-(Phenacyl)glutathione reductase; Monomethylarsonic acid reductase; MMA(V) reductase; Glutathione-dependent dehydroascorbate reductase; Glutathione S-transferase omega 1-1; GSTTLP28; GSTO-1; GSTO 1-1
Click to Show/Hide
|
|||||
Representative Drug(s) | Carfilzomib | Drug Info | IC50 = 150 nM | [5] | ||
Co-Target Name | Chymotrypsinogen B (CTRB1) | Co-Target | ||||
UniProt ID | CTRB1_HUMAN | |||||
Gene Name | CTRB1 | |||||
Representative Drug(s) | Bortezomib | Drug Info | Ki = 320 nM | [6] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Optimization of a series of dipeptides with a P3 beta-neopentyl asparagine residue as non-covalent inhibitors of the chymotrypsin-like activity of human 20S proteasome. Medchemcomm. 2012;3:710-9. | ||||
REF 2 | Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab Dispos. 2013 Jan;41(1):230-7. | ||||
REF 3 | Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives. J Med Chem. 2010 Oct 14;53(19):6779-810. | ||||
REF 4 | Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem. 2008 Feb 28;51(4):1068-72. | ||||
REF 5 | Reviewing Hit Discovery Literature for Difficult Targets: Glutathione Transferase Omega-1 as an Example. J Med Chem. 2018 Sep 13;61(17):7448-7470. | ||||
REF 6 | Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett. 1998 Feb 17;8(4):333-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.